Psoriatic Arthritis

Ongoing – Recruitment Closed

Protocol Number

Study Title

CAIN457F2336

A phase III, randomized, double-blind, placebo-controlled multicentre study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, safety and tolerability up to 2 years in patients with active PsA

CAIN457F2312

A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficacy, safety and tolerability up to 5 years in patients with Active Psoriatic Arthritis.

Trial Registration Number: NCT01752634

CAIN457F2318

A phase III, randomized, double-blind, placebo-controlledmulticenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 3 years in subjects with active Psoriatic Arthritis

Trial Registration Number: NCT01989468

CC-10004-PSA-004

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study Of Two Doses Of Apremilast (Cc-10004) In Subjects With Active Psoriatic Arthritis And A Qualifying Psoriasis Lesion

Trial Registration Number: NCT01212770

CC-10004-PSA-005

A phase 3, multicenter, randomized,Double-blind, placebo-controlled, parallelgroup, Efficacy and safety study of two doses ofApremilast (cc-10004) in subjects with active Psoriatic arthritis who have not bee Previouslytreated with disease-modifying Antirheumatic drugs

Trial Registration Number: NCT01307423